Assessment of relation between JAK2 gene and thrombosis in myeloproliferative neoplasms
نویسندگان
چکیده
Background Thrombotic complications are the most considerable etiology causing morbidity and mortality in patients with philadelphia (Ph) negative myeloproliferative neoplasms (MPN). There many studies evaluating association of JAK2 mutation risk thrombosis MPN inconclusive results. We also investigated relation between all Ph thrombosis.
 Material Methods events demographic features 177 were evaluated retrospectively.
 Results V617 F was detected 57% essential thrombocythemia (ET), %90.3 pateints polycythemia vera (PV), 100% primary myelofibrosis (PMF). occured more frequently than without (p=0.014). In JAK 2 positive groups, median age, scores leucocyte values higher, splenomegaly arterial and/or venous (p
منابع مشابه
Myeloproliferative neoplasms and thrombosis.
Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by arterial and venous complications, progression to myelofibrosis, and transformation to acute leukemia. The pathogenesis of thrombosis results from a complex interplay of clinical and disease-related factors. Abnormalities of blood cells arising from the clonal proliferation of hematopoietic stem cells inv...
متن کاملThe JAK2 gene as a protagonist in chronic myeloproliferative neoplasms
DOI: 10.5581/1516-8484.20130074 The identification of the association of a JAK2 gene mutation with chronic myeloproliferative neoplasms (cMPN) negative for BCR-ABL(1,2) has allowed significant advances in the understanding of this group of hematologic diseases. The JAK2 gene, located on chromosome 9p24, encodes the JAK2 protein which is a cytoplasmic tyrosine kinase that plays an important role...
متن کاملThe spectrum of JAK2-positive myeloproliferative neoplasms.
The discovery of the JAK2V617F mutation triggered an unexpected flowering of basic and clinical studies in the field of myeloproliferative neoplasms (MPNs), resulting after just a few years in an exceptional amount of new information. One important consequence of those new findings was the modification of the World Health Organization classification and diagnostic algorithms for these diseases,...
متن کاملAssociation of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.
Myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in Philadelphia chromosome-negative myeloproliferative neoplasms. This study correlated cytogenetic abnormalities with disease stage and JAK2 status. A total of 17...
متن کاملMyeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Most BCR-ABL1-negative myeloproliferative neoplasms (MPN) carry an activating JAK2 mutation. Approximately 96% of patients with polycythemia vera (PV) harbors the V617F mutation in JAK2 exon 14, whereas the minority of JAK2 (V617F)-negative subjects shows several mutations in exon 12. Other mutation events as MPL, TET2, LNK, EZH2 have been described in chronic phase, while NF1, IDH1, IDH2, ASX1...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Turkish journal of internal medicine
سال: 2022
ISSN: ['2687-4245']
DOI: https://doi.org/10.46310/tjim.1055305